Dyne Therapeutics, Inc. (DYN) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Waltham, MA, 미국. 현재 CEO는 John G. Cox.
DYN 을(를) 보유 IPO 날짜 2020-09-17, 192 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $3.27B.
Dyne Therapeutics, Inc. is a biotechnology company focused on developing disease-modifying therapeutics for genetically driven muscle diseases. The company leverages its proprietary FORCE platform to advance treatment programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and other rare skeletal, cardiac, and metabolic muscle diseases. Founded in 2017 and headquartered in Waltham, Massachusetts, Dyne operates primarily in the United States market, addressing significant unmet medical needs in the muscle disease therapeutic space.
